BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 12594646)

  • 21. Breaking new ground--are changes in immunization services needed for the introduction of future HIV/AIDS vaccines and other new vaccines targeted at adolescents?
    Clements CJ; Abdool-Karim Q; Chang ML; Nkowane B; Esparza J
    Vaccine; 2004 Jul; 22(21-22):2822-6. PubMed ID: 15246617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV vaccines: new frontiers in vaccine development.
    Duerr A; Wasserheit JN; Corey L
    Clin Infect Dis; 2006 Aug; 43(4):500-11. PubMed ID: 16838241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recommendations for incorporating human immunodeficiency virus (HIV) prevention into the medical care of persons living with HIV.
    ; ; ; ;
    Clin Infect Dis; 2004 Jan; 38(1):104-21. PubMed ID: 14679456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In search of a human immunodeficiency virus vaccine.
    Bartholomew CF
    West Indian Med J; 2000 Sep; 49(3):187-9. PubMed ID: 11076204
    [No Abstract]   [Full Text] [Related]  

  • 25. Potential public health impact of imperfect HIV type 1 vaccines.
    Anderson R; Hanson M
    J Infect Dis; 2005 Feb; 191 Suppl 1():S85-96. PubMed ID: 15627235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conditional live virus as a novel approach towards a safe live attenuated HIV vaccine.
    Das AT; Zhou X; Vink M; Klaver B; Berkhout B
    Expert Rev Vaccines; 2002 Oct; 1(3):293-301. PubMed ID: 12901570
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progress towards an HIV-1 subtype C vaccine.
    Nkolola JP; Essex M
    Vaccine; 2006 Jan; 24(4):391-401. PubMed ID: 16139396
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population effects of preventive and therapeutic HIV vaccines in early- and late-stage epidemics.
    Owens DK; Edwards DM; Shachter RD
    AIDS; 1998 Jun; 12(9):1057-66. PubMed ID: 9662203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Live and let live.
    Rao KS
    J Indian Med Assoc; 2002 Dec; 100(12):712, 714, 716. PubMed ID: 12793638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. No vaccine against HIV yet--are we not perfectly equipped?
    Singh M
    Virol J; 2006 Aug; 3():60. PubMed ID: 16939652
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adenoviruses as vectors for HIV vaccines.
    Gómez-Román VR; Robert-Guroff M
    AIDS Rev; 2003; 5(3):178-85. PubMed ID: 14598567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human immunodeficiency virus (HIV) vaccine trials: a novel assay for differential diagnosis of HIV infections in the face of vaccine-generated antibodies.
    Khurana S; Needham J; Mathieson B; Rodriguez-Chavez IR; Catanzaro AT; Bailer RT; Kim J; Polonis V; Cooper DA; Guerin J; Peterson ML; Gurwith M; Nguyen N; Graham BS; Golding H
    J Virol; 2006 Mar; 80(5):2092-9. PubMed ID: 16474117
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progress and obstacles in the development of an AIDS vaccine.
    Letvin NL
    Nat Rev Immunol; 2006 Dec; 6(12):930-9. PubMed ID: 17124514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The HIV vaccine].
    Smith KA
    Zhonghua Nan Ke Xue; 2004 Oct; 10(10):723-8. PubMed ID: 15562781
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Broadening inclusion of vulnerable populations in HIV vaccine trials.
    Lau CY; Cardinali M; Sato PA; Fix A; Flores J
    Expert Rev Vaccines; 2008 Mar; 7(2):259-68. PubMed ID: 18324894
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Forecasting the future of HIV epidemics: the impact of antiretroviral therapies & imperfect vaccines.
    Blower S; Schwartz EJ; Mills J
    AIDS Rev; 2003; 5(2):113-25. PubMed ID: 12876900
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Development of an AIDS vaccine: status report].
    Girard MP
    Med Trop (Mars); 2007 Aug; 67(4):340-6. PubMed ID: 17926791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evolution of HIV/AIDS prevention programs--United States, 1981-2006.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2006 Jun; 55(21):597-603. PubMed ID: 16741496
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants.
    Calarota SA; Weiner DB
    Immunol Rev; 2004 Jun; 199():84-99. PubMed ID: 15233728
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV vaccine development.
    Johnston MI
    Dev Biol (Basel); 2002; 110():57-63. PubMed ID: 12477307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.